Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence

BACKGROUND AND AIMS: Liver resection combined with postoperative sorafenib to prevent recurrence remains a controversial approach for cases of hepatocellular carcinoma (HCC), especially cases with a high risk of recurrence. This study aimed to investigate the efficacy and safety of liver resection c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Jianyong, Zhong, Jinjing, Hao, Jingcheng, Liu, Zhengni, Zhang, Peng, Wu, Lixue, Yan, Lunan, Zhu, Jinqiang, Zeng, Yong, Li, Bo, Wen, Tianfu, Wang, Wentao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173159/
https://www.ncbi.nlm.nih.gov/pubmed/26981887
http://dx.doi.org/10.18632/oncotarget.3799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173159/
https://www.ncbi.nlm.nih.gov/pubmed/26981887
http://dx.doi.org/10.18632/oncotarget.3799

Ejemplares similares